Mr. Eric Adams reports
INMED PHARMACEUTICALS APPOINTS CATHERINE SAZDANOFF TO BOARD OF DIRECTORS
Inmed Pharmaceuticals Inc. has appointed Catherine Sazdanoff, JD, to its board of directors.
Ms. Sazdanoff joins Inmed's board with 35 years of experience in the health care industry. She held various global vice-president roles in business development and corporate development at Takeda Pharmaceuticals, which she joined in 2006. Prior to Takeda, Ms. Sazdanoff served in senior global legal and pharmaceutical business roles at Abbott Laboratories since 1984, including litigation, international commercial and transactional legal roles, marketing, and business development. At both companies, she completed numerous collaborations and transformational merger and acquisition transactions, including Abbott's acquisition of Knoll Laboratories (including the megablockbuster drug Humira), and Takeda's acquisitions of Millennium Pharmaceuticals and Nycomed SA.
Ms. Sazdanoff is an independent director of the board of Meridian Bioscience Inc. She is currently president and chief executive officer of Sazdanoff Consulting LLC, where she acts as business adviser to Strata Oncology Inc., a private precision oncology company, and works with other health care companies on strategy and corporate/business development. Ms. Sazdanoff has a BA in English from the University of Notre Dame and a JD from Northwestern University School of Law.
"We are enthusiastic to welcome Catherine to our board of directors at an exciting time in the company's evolution," commented Eric A. Adams, president and chief executive officer. "Her diverse business development and legal experience, built from over 35 years in the pharmaceutical industry, will be important as we accelerate the development of our therapeutic pipeline and scale up our innovative biosynthesis platform technology. Importantly, Catherine's rich experience in pharma deal making will be highly beneficial to Inmed as our assets mature and we begin strategizing about potential transactions."
"Inmed has unique opportunities to bring significant medical advances to important patient populations with its differentiated cannabinoid-based therapeutic pipeline and novel biosynthesis manufacturing technology," stated Ms. Sazdanoff. "I am delighted to join the team and look forward to working closely with the company's management as Inmed drives towards long-term value creation."
About Inmed Pharmaceuticals Inc.
Inmed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids as well as a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs. The company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.